Resonate Blends, Inc.

What they do

The company states it is focusing on marketing licensed patent-pending natural stem cell mobilizing agents and a dual-acting all-natural diet aid. It intends to sell products under third-party label exemptions and is exploring additional bioactive formulations such as Secretogues. The company does not currently report revenue from these new products.

Revenue drivers

• Historical operations — The company reported annual revenue of $1.9 million for 2024, but the source of that revenue is not described in the provided excerpts, and the business plan has since changed.
• Licensed stem cell mobilizing agents — The company states it is focusing on marketing licensed patent-pending natural stem cell mobilizing agents, but no revenue has been reported from these products.
• Dual-acting diet aid — The company is licensed under a patent-pending application to market a dual-acting all-natural diet aid, but no revenue has been reported from this product.

Recent performance

For the quarter ended March 31, 2025, Resonate Blends reported revenue of $430,768, down from $656,228 in the quarter ended June 30, 2024. The company reported a net loss of $2.1 million for the full year 2024. As of March 31, 2025, total assets were $1.2 million, total liabilities were $6.0 million, and shareholders' equity was negative $4.2 million. Cash and cash equivalents stood at $18,117.

Strategy

Following a change in control effective March 5, 2025, James W. Zimbler was appointed President/CEO and director. The company is shifting its focus to regenerative medicine, with an emphasis on stem cell mobilization and other natural bioactive formulations. It plans to market products under third-party label exemptions and to develop products for consumer and professional markets. Research and development activities center on exploring other areas such as Secretogues.

Risks

• Going concern — The report of the independent auditors indicates uncertainty concerning the company's ability to continue as a going concern.
• Negative equity and limited cash — As of March 31, 2025, shareholders' equity was negative $4.2 million and cash was only $18,117.
• Recent business pivot — The company changed control and business plan in March 2025, and the new products have not yet generated reported revenue.
• Dependence on licensed technology — The company's new products rely on licensed patent-pending technology, and there is no assurance that these licenses will lead to successful commercialization.

Outlook

Management has not provided specific financial guidance in the excerpts. The company is expected to focus on executing its new business plan in regenerative medicine. Additional information about the new business plan is referenced in Current Reports on Form 8-K filed August 12, 2024, and March 14, 2025.